MTMR2

Across TCGA pan-cancer cohorts, MTMR2 mass-spec protein is linked to patient survival in 8 of 34 cancer types, making it a survival-associated MTMR2 data layer compared with 29 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher MTMR2 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated MTMR2 expression acts as an unfavorable survival marker, although some lineages such as CCRCC show a favorable association.

CCRCC, PDAC, and COAD are the cancer types where MTMR2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	II,III,IV	1.000	0.514	.022	18	view →
PDAC	DFS	Median	IV	0.214	0.785	.006	12	view →
COAD	DFS	Median	IV	0.565	1.000	.028	6	view →
LSCC	DFS	Median	II,III,IV	0.862	0.965	.030	5	view →
UCEC	OS	Tertile	III,IV	0.502	1.000	.042	4	view →
LUAD	OS	Quartile	All	0.908	1.000	.026	4	view →
GBM	OS	Quartile	All	0.279	0.657	.025	2	view →
HNSC	DFS	Tertile	IV	0.569	0.828	.044	2	view →

Pink = unfavorable, green = favorable. Showing the 8 strongest of 8 lineages.

MTMR2–CCRCC (DFS)

Open the CCRCC breakdown →